Last reviewed 2026-04-20 · How we verify

LN group

At a glance

Approved indications

No approved indications tracked.

Common side effects

• Anaemia
• Thrombocytopenia [4]
• Chills
• Nausea
• Leukopenia [1]
• Febrile neutropenia
• Neutropenia [3]
• Diarrhoea
• Vomiting
• Pyrexia
• Fatigue
• Oedema peripheral

Key clinical trials

• A Research Trial to Assess if Cenerimod is Efficacious and Safe to Treat Active Lupus Nephritis on Top of Regular Treatment (PHASE3)
• Therapeutic Drug Monitoring of Mycophenolate Mofetil in Lupus Nephritis (NA)
• Study of Lifileucel (LN-144), Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic Melanoma (PHASE2)
• Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis (PHASE3)
• Evaluation of Sentinel Node Policy in Early Stage Endometrial Carcinomas at Intermediate and High Risk of Recurrence. (PHASE3)
• The Efficacy and Safety of Biologics (Belimumab/ Telitacicept) Induction Therapy in Proliferative Lupus Nephritis Patients for 6 Months Compared With Mycophenolate Mofetil Treatment (PHASE2)
• Phase III Extension Study of Efficacy and Safety of Ianalumab With or Without Study Treatment Withdrawal in Participants With Lupus Nephritis (SIRIUS-LN Extension) (PHASE3)
• Heart Rate Variability Guided Physical Activity and Exercise Prescription in Individuals With Knee Osteoarthritis (NA)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.